Chk1 inhibitor ly2603618

Manufactured by Selleck Chemicals

Chk1 inhibitor LY2603618 is a chemical compound used in laboratory research. It functions as an inhibitor of the Chk1 protein, which plays a role in cell cycle regulation and DNA damage response. This product is intended for use in scientific research applications.

Automatically generated - may contain errors

Lab products found in correlation

4 hydroxytamoxifen 4 oht, by Merck Group (1 mentions) Colcemid, by Roche (1 mentions) Ro 3306, by Selleck Chemicals (1 mentions) Ve 821, by Selleck Chemicals (1 mentions)

Spelling variants of this product

LY2603618 (37 citations) Chk1 inhibitor (2 citations)

2 protocols using chk1 inhibitor ly2603618

Optimizing Cytotoxic Drug Sensitivity

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The day after miRNAs/siRNA transfection, cells were exposed to drug treatments at indicated doses/times. In clonogenic assays Cis-platinum (Pt) (TEVA Italia) was used at doses ranging from 0.1 to 1μM. As described (21 (link)), this assay required a lower Pt concentration than that required for the DNA damage assay that is performed at Pt doses corresponding to the IC50 of each cell line as previously defined by TiterGlo or SRB assays (22 (link)). For SKOV3 cells also the sub-citotoxic IC30 Pt dose corresponding to 1μM was used. Chk1 inhibitor LY2603618 (Selleckchem) and Wee1 inhibitor MK1775 (Biovision) were reconstituted in dimethyl sulfoxide (DMSO) and used at doses ranging from 50 to 500nM and from 50 to 200nM, respectively. For all assays, drugs were diluted in cell culture media.

Bagnoli M., Nicoletti R., Valitutti M., Rizzo A., Napoli A., Montalvão De Azevedo R., Tomassetti A, & Mezzanzanica D. (2022). Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. Frontiers in Oncology, 12, 923508.

+ Open protocol

+ Expand

Inducible TRF1-FokI System for Cellular G2 Arrest

Check if the same lab product or an alternative is used in the 5 most similar protocols

Doxycycline was used at a concentration of 40 ng ml⁻¹ for 16–24 h to induce expression of TRF1–FokI. Shield-1 (Cheminpharma LLC) and 4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) were both used at a concentration of 1 μM for 2 h, unless otherwise stated, in to allow for TRF1–FokI stabilization and translocation into the nucleus. RO-3306 (Selleck Chemicals) was used at a concentration of 10 μM for 20–24 h. G2 enrichment was confirmed by propidium iodide staining and flow cytometry. Colcemid (Roche) was used at a concentration of 100 ng ml⁻¹. The ATR inhibitor VE-821 (Selleck Chemicals) and Chk1 inhibitor LY2603618 (Selleck Chemicals) were used at a concentration of 5 μM and 1 μM respectively for 24 h.

Dilley R.L., Verma P., Cho N.W., Winters H.D., Wondisford A.R, & Greenberg R.A. (2016). Break-induced telomere synthesis underlies alternative telomere maintenance. Nature, 539(7627), 54-58.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!